2025-05-15-Jefferies-EDAP_TMS（EDAP）_第一季度表现喜忧参半F1设备安装量增加_高强度聚焦超声（HIFU）销量增速放缓；可能进行资本筹集；目标价1.75美元_10页_639kb

Company Overview: EDAP TMS develops and commercializes minimally invasive ultrasound devices for treating prostate cancer and urinary stones, focusing on products like HIFU (High-Intensity Focused Ultrasound) systems.

Recent Performance: In Q1 2025, sales declined 11% year-over-year to $14 million, missing consensus estimates of $17 million. However, there were 9 Focal One system placements, exceeding the 5 system forecast by Jefferies. HIFU procedure growth slowed to 4% YoY due to payer pushback, impacting revenue; non-core businesses like Lithotripsy saw a 19% decline in sales.

Analyst Ratings: The equity research maintains a Hold rating with a price target lowered to $1.75, reflecting a 2% decrease from the prior target, due to a Q1 sales miss. This assessment incorporates revised FY2025 estimates based on slower performance.

Future Guidance: EDAP reiterated its FY2025 guidance for HIFU sales growth of 16-25% and a 20-25% decline in non-core ESWL and Distribution sales. The weakened guidance introduces increased risk to growth projections, as per Jefferies.

Investment Thesis: Jefferies expects continued progress in Focal One HIFU penetration in the U.S. for prostate cancer, potentially driving revenue. However, they argue consensus estimates for HIFU and total sales are overly optimistic. Upside catalysts include enhanced HIFU adoption and regulatory approval for deep infiltrating endometriosis, while downside risks include supply chain disruptions from climate events, regulatory challenges, and a 20% tariff on US-bound goods from France, estimated to cost $300,000–$400,000 quarterly on COGS.

Financials: Q1 cash burn was approximately $6.7 million, up from $0 in Q4 2024, with $25 million in cash reserves. Financial exhibits show revenue declines in non-core segments and operating losses, highlighting burn rates and profitability issues. Projections indicate a 4% sales CAGR over three years, incorporating HIFU growth.

Valuation: The price target of $1.75 is based on 0.5-1x EV/sales for FY2026. Upside scenarios include faster HIFU adoption and market expansion, while downside risks involve competition, reimbursement issues, and macroeconomic headwinds.